FDA knocks back ViiV, J&J’s long-acting HIV regimen

ViiV presses go on FDA filing for first-in-class HIV drug fo...

ViiV files monthly HIV jab in Europe

ViiV’s first-in-class HIV drug on course for filings this ye...

GSK’s monthly HIV treatment breakthrough

GlaxoSmithKline has seen positive clinical results from the phase 3 study of its once-monthly injectable HIV treatment, stepping closer to potentially changing lives of patients living with

ViiV prepares another two-drug HIV filing

ViiV Healthcare says it is on course to change standard care in HIV treatment by providing another combination cutting the number of drugs taken to suppress the disease from three to two, f